Year-long COVID-19 infection reveals within-host evolution of SARS-CoV-2 in a patient with B cell depletion.


Journal

medRxiv : the preprint server for health sciences
Titre abrégé: medRxiv
Pays: United States
ID NLM: 101767986

Informations de publication

Date de publication:
05 Oct 2021
Historique:
entrez: 13 10 2021
pubmed: 14 10 2021
medline: 14 10 2021
Statut: epublish

Résumé

B-cell depleting therapies may lead to protracted disease and prolonged viral shedding in individuals infected with SARS-CoV-2. Viral persistence in the setting of immunosuppression raises concern for viral evolution. Amplification of sub-genomic transcripts for the E gene (sgE) was done on nasopharyngeal samples over the course of 355 days in a patient infected with SARS-CoV-2 who had previously undergone CAR T cell therapy and had persistently positive SARS-CoV-2 nasopharyngeal swabs. Whole genome sequencing was performed on samples from the patient's original presentation and 10 months later. Over the course of almost a year, the virus accumulated a unique in-frame deletion in the amino-terminal domain of the spike protein, and complete deletion of ORF7b and ORF8, the first report of its kind in an immunocompromised patient. Also, minority variants that were identified in the early samples-reflecting the heterogeneity of the initial infection-were found to be fixed late in the infection. Remdesivir and high-titer convalescent plasma treatment were given, and the infection was eventually cleared after 335 days of infection. The unique viral mutations found in this study highlight the importance of analyzing viral evolution in protracted SARS-CoV-2 infection, especially in immunosuppressed hosts, and the implication of these mutations in the emergence of viral variants. We report an immunocompromised patient with persistent symptomatic SARS-CoV-2 infection for 335 days. During this time, the virus accumulated a unique in-frame deletion in the spike, and a complete deletion of ORF7b and ORF8 which is the first report of its kind in an immunocompromised patient.

Sections du résumé

BACKGROUND BACKGROUND
B-cell depleting therapies may lead to protracted disease and prolonged viral shedding in individuals infected with SARS-CoV-2. Viral persistence in the setting of immunosuppression raises concern for viral evolution.
METHODS METHODS
Amplification of sub-genomic transcripts for the E gene (sgE) was done on nasopharyngeal samples over the course of 355 days in a patient infected with SARS-CoV-2 who had previously undergone CAR T cell therapy and had persistently positive SARS-CoV-2 nasopharyngeal swabs. Whole genome sequencing was performed on samples from the patient's original presentation and 10 months later.
RESULTS RESULTS
Over the course of almost a year, the virus accumulated a unique in-frame deletion in the amino-terminal domain of the spike protein, and complete deletion of ORF7b and ORF8, the first report of its kind in an immunocompromised patient. Also, minority variants that were identified in the early samples-reflecting the heterogeneity of the initial infection-were found to be fixed late in the infection. Remdesivir and high-titer convalescent plasma treatment were given, and the infection was eventually cleared after 335 days of infection.
CONCLUSIONS CONCLUSIONS
The unique viral mutations found in this study highlight the importance of analyzing viral evolution in protracted SARS-CoV-2 infection, especially in immunosuppressed hosts, and the implication of these mutations in the emergence of viral variants.
SUMMARY CONCLUSIONS
We report an immunocompromised patient with persistent symptomatic SARS-CoV-2 infection for 335 days. During this time, the virus accumulated a unique in-frame deletion in the spike, and a complete deletion of ORF7b and ORF8 which is the first report of its kind in an immunocompromised patient.

Identifiants

pubmed: 34642697
doi: 10.1101/2021.10.02.21264267
pmc: PMC8509089
pii:
doi:

Types de publication

Preprint

Langues

eng

Commentaires et corrections

Type : UpdateIn

Références

Bioinformatics. 2009 Jul 15;25(14):1754-60
pubmed: 19451168
Cell. 2020 May 14;181(4):914-921.e10
pubmed: 32330414
Sci Transl Med. 2021 Jan 27;13(578):
pubmed: 33431511
Nat Med. 2020 Feb;26(2):270-280
pubmed: 31959992
Nat Microbiol. 2021 Mar;6(3):415
pubmed: 33514928
Clin Immunol. 2021 Jun;227:108723
pubmed: 33838340
Nature. 2021 Apr;592(7853):277-282
pubmed: 33545711
Glob Chall. 2017 Jan 10;1(1):33-46
pubmed: 31565258
mBio. 2020 Jul 21;11(4):
pubmed: 32694143
Emerg Microbes Infect. 2020 Dec;9(1):1457-1466
pubmed: 32543353
Nat Microbiol. 2020 Nov;5(11):1403-1407
pubmed: 32669681
Science. 2020 Oct 30;370(6516):564-570
pubmed: 32912998
Cell. 2020 Oct 1;183(1):158-168.e14
pubmed: 32979941
Infect Genet Evol. 2020 Nov;85:104525
pubmed: 32890763
BMC Evol Biol. 2004 Jun 28;4:21
pubmed: 15222897
Bioinformatics. 2014 Aug 1;30(15):2114-20
pubmed: 24695404
Nat Immunol. 2020 Oct;21(10):1293-1301
pubmed: 32807944
Clin Infect Dis. 2021 Aug 2;73(3):e815-e821
pubmed: 33507235
Cell Host Microbe. 2021 May 12;29(5):819-833.e7
pubmed: 33789084
Cell Rep. 2021 Feb 9;34(6):108728
pubmed: 33516277
Nature. 2020 May;581(7809):465-469
pubmed: 32235945
Cell. 2020 Dec 23;183(7):1901-1912.e9
pubmed: 33248470
Bioinformatics. 2018 Dec 1;34(23):4121-4123
pubmed: 29790939
Lancet Microbe. 2021 Jan;2(1):e13-e22
pubmed: 33521734
Lancet. 2020 Aug 29;396(10251):603-611
pubmed: 32822564
Transfus Apher Sci. 2020 Oct;59(5):102871
pubmed: 32694044
N Engl J Med. 2020 Dec 3;383(23):2291-2293
pubmed: 33176080
Nat Rev Immunol. 2020 Jul;20(7):392-394
pubmed: 32514035

Auteurs

Veronique Nussenblatt (V)

Laboratory of Clinical Immunology and Microbiology, NIAID, NIH, Bethesda, MD 20854, USA.

Allison E Roder (AE)

Systems Genomics Section, Laboratory of Parasitic Diseases, DIR, NIAID, NIH, Bethesda, MD 20894, USA.

Sanchita Das (S)

Department of Laboratory Medicine, NIH, Bethesda, MD 20894, USA.

Emmie de Wit (E)

Laboratory of Virology, DIR, NIAID, NIH, Hamilton, MT, USA.

Jung-Ho Youn (JH)

Department of Laboratory Medicine, NIH, Bethesda, MD 20894, USA.

Stephanie Banakis (S)

Systems Genomics Section, Laboratory of Parasitic Diseases, DIR, NIAID, NIH, Bethesda, MD 20894, USA.

Alexandra Mushegian (A)

Systems Genomics Section, Laboratory of Parasitic Diseases, DIR, NIAID, NIH, Bethesda, MD 20894, USA.

Christopher Mederos (C)

Systems Genomics Section, Laboratory of Parasitic Diseases, DIR, NIAID, NIH, Bethesda, MD 20894, USA.

Wei Wang (W)

Systems Genomics Section, Laboratory of Parasitic Diseases, DIR, NIAID, NIH, Bethesda, MD 20894, USA.

Matthew Chung (M)

Systems Genomics Section, Laboratory of Parasitic Diseases, DIR, NIAID, NIH, Bethesda, MD 20894, USA.

Lizzette Pérez-Pérez (L)

Laboratory of Virology, DIR, NIAID, NIH, Hamilton, MT, USA.

Tara Palmore (T)

Clinical Center, NIH, Bethesda, MD 20854, USA.

Jennifer N Brudno (JN)

Surgery Branch, Center for Cancer Research, NCI, NIH, Bethesda, MD 20894, USA.

James N Kochenderfer (JN)

Surgery Branch, Center for Cancer Research, NCI, NIH, Bethesda, MD 20894, USA.

Elodie Ghedin (E)

Systems Genomics Section, Laboratory of Parasitic Diseases, DIR, NIAID, NIH, Bethesda, MD 20894, USA.

Classifications MeSH